Eurizon Capital SGR S.p.A. cut its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 6.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,414,037 shares of the company’s stock after selling 101,122 shares during the quarter. AbbVie comprises about 1.0% of Eurizon Capital SGR S.p.A.’s investment portfolio, making the stock its 19th biggest position. Eurizon Capital SGR S.p.A.’s holdings in AbbVie were worth $370,620,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds also recently added to or reduced their stakes in the stock. Werba Rubin Papier Wealth Management raised its stake in shares of AbbVie by 7.5% during the third quarter. Werba Rubin Papier Wealth Management now owns 4,543 shares of the company’s stock valued at $1,188,000 after purchasing an additional 317 shares during the period. Van Strum & Towne Inc. boosted its stake in shares of AbbVie by 1.2% in the third quarter. Van Strum & Towne Inc. now owns 38,213 shares of the company’s stock valued at $9,996,000 after purchasing an additional 440 shares during the period. Three Bridge Wealth Advisors LLC purchased a new position in shares of AbbVie in the third quarter valued at $132,000. Endeavor Private Wealth Inc. boosted its stake in shares of AbbVie by 8.6% in the third quarter. Endeavor Private Wealth Inc. now owns 2,652 shares of the company’s stock valued at $693,000 after purchasing an additional 209 shares during the period. Finally, Banyan Capital Management Inc. acquired a new stake in AbbVie during the 3rd quarter valued at $737,000. 70.23% of the stock is owned by hedge funds and other institutional investors.
More AbbVie News
Here’s some of the latest news about ABBV:
- Positive Sentiment: AbbVie’s immunology sales rose 16.6% in the third quarter, with Skyrizi and Rinvoq growth more than offsetting Humira’s decline. The performance has supported higher 2026 sales expectations and strengthens the case that newer drugs can sustain growth. How Did AbbVie’s Immunology Franchise Fare in Q3?
- Positive Sentiment: AbbVie recently raised its 2026 revenue guidance to about $67.8 billion and increased its dividend after reporting third-quarter revenue of $17.4 billion. These updates reinforce the company’s earnings and shareholder-return outlook. Can AbbVie Justify Its Valuation After Raised Guidance and Strong Results?
- Negative Sentiment: Executive Vice President Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. Insider sales can weigh on sentiment, though the filing does not explain the reason for the transaction. SEC Form 4 filing
Insider Activity
In other news, EVP Jeffrey Stewart sold 40,619 shares of the stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the transaction, the executive vice president owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. This trade represents a 32.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.
Analyst Ratings Changes
Several research firms recently issued reports on ABBV. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and lifted their price target for the stock from $235.00 to $300.00 in a research note on Thursday, August 13th. Wells Fargo & Company upped their price objective on shares of AbbVie from $300.00 to $340.00 and gave the company an “overweight” rating in a research report on Monday, November 2nd. HSBC raised their target price on AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Canaccord Genuity Group lifted their target price on AbbVie from $290.00 to $338.00 and gave the stock a “buy” rating in a research report on Monday, November 2nd. Finally, Guggenheim boosted their price target on AbbVie from $288.00 to $322.00 and gave the stock a “buy” rating in a research note on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $297.46.
Read Our Latest Research Report on ABBV
AbbVie Trading Down 0.1%
Shares of NYSE:ABBV opened at $294.75 on Friday. The company has a fifty day simple moving average of $274.82 and a 200 day simple moving average of $240.55. The firm has a market cap of $521.01 billion, a PE ratio of 50.73, a price-to-earnings-growth ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $302.93.
AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The firm had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same period in the prior year, the firm posted $1.86 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. As a group, equities research analysts forecast that AbbVie Inc. will post 13.98 EPS for the current fiscal year.
AbbVie Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be paid a $1.82 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. AbbVie’s dividend payout ratio (DPR) is currently 119.10%.
AbbVie Company Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
See Also
- Five stocks we like better than AbbVie
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
